Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY231 in Relapsed or Refractory B-cell Lymphoma/Leukemia
NCT06689917Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY231 in B cell lymphoma and B-cell leukemia (BCL), sponsored by Tongji Hospital. Primary endpoints: Incidence of adverse events at Month 24 and Maximal Tolerated Dose at 28 days. Started Jan 2025; status: recruiting.
02
Drugs
JY231
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT06689917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689917.